PMID- 20677284
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20100802
IS  - 1527-6473 (Electronic)
IS  - 1527-6465 (Linking)
VI  - 16
IP  - 8
DP  - 2010 Aug
TI  - Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, 
      limitations, and analysis of the current literature.
PG  - 930-42
LID - 10.1002/lt.22106 [doi]
AB  - Orthotopic liver transplantation (OLT) is currently incorporated into the 
      treatment regimens for specific nonhepatocellular malignancies. For patients 
      suffering from early-stage, unresectable hilar cholangiocarcinoma (CCA), OLT 
      preceded by neoadjuvant radiotherapy has the potential to readily achieve a 
      tumor-free margin, accomplish a radical resection, and treat underlying primary 
      sclerosing cholangitis when present. In highly selected stage I and II patients 
      with CCA, the 5-year survival rate is 80%. As additional data are accrued, OLT 
      with neoadjuvant chemoradiation may become a viable alternative to resection for 
      patients with localized, node-negative hilar CCA. Hepatic involvement from 
      neuroendocrine tumors can be treated with OLT when metastases are unresectable or 
      for palliation of medically uncontrollable symptoms. Five-year survival rates as 
      high as 90% have been reported, and the Ki67 labeling index can be used to 
      predict outcomes after OLT. Hepatic epithelioid hemangioendothelioma is a rare 
      tumor of vascular origin. The data from single-institution series are limited, 
      but compiled reviews have reported 1- and 10-year survival rates of 96% and 72%, 
      respectively. Hepatoblastoma is the most common primary hepatic malignancy in 
      children. There exist subtle differences in the timing of chemotherapy between US 
      and European centers; however, the long-term survival rate after transplantation 
      ranges from 66% to 77%. Fibrolamellar hepatocellular carcinoma is a distinct 
      liver malignancy best treated by surgical resection. However, there is an 
      increasing amount of data supporting OLT when resection is contraindicated. In 
      the treatment of either primary or metastatic hepatic sarcomas, unacceptable 
      survival and recurrence rates currently prohibit the use of OLT.
CI  - (c) 2010 AASLD.
FAU - Grossman, Eric J
AU  - Grossman EJ
AD  - Section of Transplantation, Department of Surgery, University of Chicago Medical 
      Center, Chicago, IL 60637, USA.
FAU - Millis, J Michael
AU  - Millis JM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Aged
MH  - Cholangiocarcinoma/therapy
MH  - Hemangioendothelioma/therapy
MH  - Hepatoblastoma/therapy
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Liver/pathology
MH  - Liver Neoplasms/*therapy
MH  - Liver Transplantation/*methods
MH  - Medical Oncology/methods
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neuroendocrine Tumors/therapy
MH  - Sarcoma/therapy
MH  - Treatment Outcome
EDAT- 2010/08/03 06:00
MHDA- 2010/11/17 06:00
CRDT- 2010/08/03 06:00
PHST- 2010/08/03 06:00 [entrez]
PHST- 2010/08/03 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - 10.1002/lt.22106 [doi]
PST - ppublish
SO  - Liver Transpl. 2010 Aug;16(8):930-42. doi: 10.1002/lt.22106.